Cancer Prevention II: 181 (Recent Results in Cancer Research) - Tapa dura

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland―and we fear in many other parts of the globe―some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

This "Recent Results in Cancer Research" volume contains the majority of the invited expert contributions of the Fifth International Conference on Cancer Prevention, held 6-8 March 2008 at the University of St. Gallen, Switzerland. Written by some of the world's leading experts in the field, the volume constitutes a comprehensive update on the most important and recent developments in molecular biology and cancer genetics, regarding chiefly the upsurging, but still controversial, field of primary prevention, especially chemoprevention. This conference primarily addressed the four leading and most frequent solid tumor types - breast, colon, gynecological, and lung cancer - all of which demonstrate how such an approach is currently possible and important in clinical cancer prevention research. The future prospects of chemoprevention and the process of selecting the most successful target populations at risk are discussed.